Various imaging modalities show low sensitivity for detecting pelvic lymph node invasion prior to surgery in patients with intermediate risk prostate cancer.

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient has been dosed in the Phase 3 registration study of TLX591-Px (Illuccix®, Kit for the preparation ...

PSMA-PET molecular imaging more often triggers changes in salvage radiation treatment compared with usual care. Prostate-specific membrane antigen positron emission tomography (PSMA-PET) imaging ...

On 16 January 2026, Telix Pharmaceuticals announced that the first U.S. patient had been dosed in BiPASS, a Phase 3 trial ...

Prostate-specific membrane antigen (PSMA)-PET/CT imaging identified metastatic prostate cancer in almost half of high-risk cases missed by conventional imaging, a retrospective analysis showed.

Study findings support PSMA-PET as a first-line approach for the primary staging of intermediate- to high-risk prostate cancer. In head-to-head comparisons, prostate-specific membrane antigen positron ...

Illuccix, after radiolabelling with gallium-68, is indicated in France for the detection of prostate-specific membrane antigen (PSMA)-positive lesions with PET in adults with prostate cancer (PCa) in ...

A molecular imaging tool developed by researchers at the University of California’s two nationally ranked medical centers, UCLA and UCSF, helps improve the accuracy of predicting the risk of cancer ...

A new radioactive diagnostic agent for use in prostate cancer has been approved by the US Food and Drug Administration (FDA). The product, Gallium 68 PSMA-11 (Ga 68 PSMA-11), has been approved for ...

NUCLIDIUM AG, a clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform, today announced that U.S. Patent No. 12,527,885 has been granted by the United ...

Reston, VA—In elderly patients with suspected prostate cancer, PSMA PET/CT can diagnose advanced disease and aid in therapy selection without the need for a biopsy. Published in the July issue of The ...